Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Phospholipase C eta-1 (PLCH1) is an enzyme of the phosphoinositide-specific phospholipase C family, involved in the hydrolysis of phosphatidylinositol 4,5-bisphosphate (PtdIns(4,5)P2) to generate the second messengers diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3), a process critical for intracellular calcium signaling. PLCH1 features conserved domains typical of the PLC-eta family, including pleckstrin homology, EF-hand, C2, and catalytic X and Y domains, and is predominantly expressed in neuronal tissues and lung. Functional studies indicate essential roles in central nervous system signaling and neurodevelopment, with pathogenic variants causing holoprosencephaly spectrum disorders. Polymorphisms in PLCH1 are also associated with increased lung cancer risk, highlighting its involvement in both physiological signaling and disease pathogenesis.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Phospholipase C eta-1 (PLCH1).